Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 43.25

Bid: 42.50

Ask: 44.00

Change: 3.00 (7.32%)

Spread: 1.50 (3.529%)

Open: 42.25

High: 44.00

Low: 44.00

Prev. Close: 41.00

Last checked at -

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Mon, 10th May 2021 11:13

Avacta Group PLC - Yorkshire-based drug and diagnostic equipment developer - Submits declaration of conformity for rapid Covid-19 lateral flow test to the UK's Medicines & Healthcare Products Regulatory Agency. Expects registration of test to be confirmed in the coming days, before it is immediately placed on the market. The test has been shown to be more sensitive than lateral flow tests currently on the market, particularly for lower viral loads.

Current stock price: 266.88 pence, up 1.9% on Monday

Year-to-date change: more than doubled from 114.0p on December 31

By Ivan Edwards; ivanedwards@alliancenews.com

More News

9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

8 Mar 2021 19:07

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

8 Mar 2021 11:06

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

24 Feb 2021 11:45

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

22 Feb 2021 11:01

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

22 Feb 2021 09:28

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

22 Feb 2021 08:54

Avacta clarifies reports on potential use of its Covid-19 test

(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.

22 Feb 2021 08:47

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

18 Feb 2021 14:31

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

18 Feb 2021 08:49

Avacta gets approval for first-in-human study of AVA6000

(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.

16 Feb 2021 11:31

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Avacta enters licence deal with Werfen subsidiary Biokit

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

Avacta confirms efficacy of test on variant Covid-19 strains

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Avacta clarifies reports on potential use of its Covid-19 test

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

Avacta gets approval for first-in-human study of AVA6000

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Avacta upbeat on initial data for Covid-19 rapid test study

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Login to your account

Quickpicks are a member only feature

Login to your account